Bykov VV, Leonov KA, Serebrov VY, Chernysheva GA, Smol'yakova VI, Solov'ev MA, Udut EV, Fisenko VP, Udut VV. Metabolism of a New Antiaggregant, Indolinone Derivative.
Bull Exp Biol Med 2020;
168:739-742. [PMID:
32333310 DOI:
10.1007/s10517-020-04792-y]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Indexed: 11/26/2022]
Abstract
Cytochrome p450-mediated metabolism of GRS (indolinone antiaggregant) and its effects on activities of cytochrome p450 isoenzymes were studied. Inhibition of 6 isomers of cytochrome p450 in human liver microsomes was studied with the use of specific substrates. It was found that human liver cytochrome p450 enzymes could not induce degradation of GRS and that GRS was not an inductor or inhibitor of cytochrome p450 family members 1A2, 2C9, 2C19, 2D6, 2C8, and 3A4. Hence, clinical use of the prospective antiaggregant would not involve the risk of uncontrolled fluctuations in GRS concentrations in the organism because of interactions between the drugs.
Collapse